Entrar/Registro  
INICIO ENGLISH
 
Cirujano General
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Cirujano General >Año 2011, No. S1


Medina FH
Avances en el diagnóstico y tratamiento del cáncer de mama
Cir Gen 2011; 33 (S1)

Idioma: Español
Referencias bibliográficas: 28
Paginas: 35-38
Archivo PDF: 167.30 Kb.


Texto completo




FRAGMENTO

El cáncer de mama es un problema de salud pública mundial y nacional. Actualmente es la primera neoplasia maligna por su frecuencia en el sexo femenino y la segunda causa de mortalidad por cáncer en mujeres mexicanas, sólo por detrás del cáncer pulmonar. Por su gran frecuencia en países de primer mundo es una de las neoplasias malignas en las que se realiza más investigación.


Palabras clave: Sin palabras Clave


REFERENCIAS

  1. Bernard JR, Vallow LA, De Peri DG, et al. Mammographically occult contralateral breast carcinoma detected by magnetic resonance imaging in the elderly. Proc Am Soc Clin Oncol 2008; 26: 7S (Abstr 500).

  2. Katipamula R, Hoskin TL, Boughey AC, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative MRI. Proc Am Soc Clin Oncol 2008; 26: 9S (Abstr 509).

  3. Medina-Franco H, Urist MM. Occult breast carcinoma presenting with axillary lymph node metastasis. Rev Invest Clin 2002; 54: 204-208.

  4. Gilbert FJ, Astley SM, Gillan MG, et al. CADET II: A prospective trial of computer-aided detection (CAD) in the UK Breast Screening Programme. Proc Am Soc Clin Oncol 2008; 26: 8S (Abstr 508).

  5. Medina-Franco H, Beenken SW, Heslin MJ, Salter M, Urist MM. Local recurrence after breast conserving therapy for invasive breast cancer: analysis of prognostic factors. Rev Oncol 2003; 5: 93-97.

  6. Guirguis LM, Bauer KR, Parise CA, Brown M. Breast conserving surgery use among California Latinas. Ann Surg Oncol 2008; 15: 39 (Abstr P21).

  7. Demore DW, Ollila EC, Dees EC, et al. Locoregional control in locally advanced breast cancer using neoadjuvant chemotherapy followed by breast conservation. Proc Am Soc Clin Oncol 2008; 26: 15S (Abstr 539).

  8. Medina-Franco H, Vasconez LO, Fix JR, Heslin MJ, Beenken SW, Bland KI, Urist MM. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 2002; 235: 814-819.

  9. Mizuta N, Nakayima H, Fujiwara I, Sakaguchi K, Hachimine Y. Endoscopic skin-sparing breast-conserving surgery for breast cancer and immediate reconstruction with autologous tissue. Proc Am Soc Clin Oncol 2008; 26: 15S (Abstr 539).

  10. Pritchard KI, Julian J, McCready D, et al. A prospective study evaluating 18F-fluorodeoxiglucose positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer. Proc Am Soc Clin Oncol 2008; 26: 14S (Abstr 533).

  11. Medina-Franco H. Actualidades en el manejo quirúrgico del cáncer de mama. Rev Invest Clin 2003; 55: 557-568.

  12. Vergara-Fernandez O, Cortés-González R, Medina-Franco H. Validación del ganglio centinela en cáncer de mama con dos técnicas. Rev Invest Clin 2004; 56: 309-313.

  13. Kell MR, Burke J, Morrow M. Outcome following axillary staging in early breast cancer. Proc Am Soc Clin Oncol 2008; 26: 16S (Abstr 543).

  14. Koostra JJ, Hoekstra-Weebers JE, Rietman J, et al. Quality of life after sentinel node dissection in stage I/II breast cancer patients: a prospective longitudinal study. Ann Surg Oncol 2008; 15: 29 (Abstr 88).

  15. Saha S, Sirop SJ, Fritz P, et al. Comparative analysis of sentinel lymph node mapping in breast cancer by 1% lymphazurin vs 1% methylene blue: a prospective study. Proc Am Soc Clin Oncol 2008; 26: 23S (Abstr 570).

  16. Langer I, Guller U, Viehl CT, Moch H, Wight E, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases can be safely omitted in early breast cancer patients: long-term outcomes of a prospective observational study. Ann Surg Oncol 2008; 15: 9 (Abstr 22).

  17. Sanghani M, Balk EM, Cady B. A systematic review and meta-analysis of randomized trials assessing the impact of axillary lymph node dissection on breast cancer outcome in clinically node negative patients. Ann Surg Oncol 2008; 15: 26 (Abstr 79).

  18. Pulgiese M, Stempel M, Patil S, et al. The clinical impact of immunohistochemistry-only metastases in breast cancer. J Clin Oncol 2009; 27: 34s.

  19. Pulgiese M, Karma A, Hsu M, et al. Sentinel node immunohistochemical metastases in breast cancer: Prognostic factors, treatment patterns, and outcomes associated with axillary lymph node dissection. Ann Surg Oncol 2009; 16: 47.

  20. Tjan-Heijnen V, Pepels M, De Boer M, et al. Impact of omission of completion axillary lymph node dissection or axillary radiotherapy in breast cancer patients with micrometastases or isolated tumor cells in the sentinel lymph node: Results from the MIRROR study. J Clin Oncol 2009; 27: 803s.

  21. Nathan NR, Michaelson JS, Cady B. Matched pair analysis of stage 4 breast cancer with resection of primary breast site. Ann Surg Oncol 2008; 15: 2 (Abstr 2).

  22. Leung AM, Nguyen KT, Thacker LR, Bear HD, Vu HN. Effects of locoregional control of primary breast tumor on patient survival in stage IV metastatic breast cancer. Ann Surg Oncol 2008; 15: 8 (Abstr 20).

  23. MacFarlane R, Speers C, Masoudi H, Chia S. Molecular changes in the primary breast cancer versus the relapsed/metastatic lesion from a large population-based database and tissue microarray series. Proc Am Soc Clin Oncol 2008; 26: 41S (Abstr 1000).

  24. Leitzel K, Lipton A, Koestler W, et al. Use of total HER2 and HER2 homodimer levels to predict response to trastuzumab. Proc Am Soc Clin Oncol 2008; 26: 41S (Abstr 1002).

  25. O´Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Proc Am Soc Clin Oncol 2008; 26: 44S (Abstr 1015).

  26. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC):AVADO. Proc Am Soc Clin Oncol 2008; 26: 43S (Abstr 1011).

  27. Nikolic S, Inic M, Martinovic A, et al. Surgical treatment of liver metastases due to breast cancer. Ann Surg Oncol 2008; 15: 38 (Abstr P17).

  28. Medina-Franco H, Garza-Montufar E, Gabilondo B, Gaona-Luviano P. Riesgo de cáncer de mama invasor en población mexicana y patrones de escrutinio y profilaxis. Rev Invest Clin 2004; 56: 422-426.



>Revistas >Cirujano General >Año2011, No. S1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019